BI developing combinations with its own checkpoint inhibitors
BI boosted by new diabetes and respiratory drugs.
AZ hopes data will boost sales of its Farxiga.
Balancing innovation and huge unmet patient need with burgeoning cost constraints.
Lilly/Boehringer gain further advantage in US diabetes market.
Sanofi under pressure following long-awaited biosimilar launch.
Companies’ actions discredited the industry, says PMCPA.
Long-release pill is eighth drug to come from diabetes partnership.